6190 — PhoenixBio Co Income Statement
0.000.00%
Last trade - 00:00
- ¥2bn
- ¥1bn
- ¥2bn
- 25
- 57
- 19
- 21
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,228 | 1,311 | 1,014 | 1,325 | 2,124 |
Cost of Revenue | |||||
Gross Profit | 851 | 866 | 588 | 728 | 1,556 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,556 | 1,750 | 1,290 | 1,757 | 1,616 |
Operating Profit | -327 | -439 | -277 | -433 | 508 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -295 | -418 | -224 | -393 | 511 |
Provision for Income Taxes | |||||
Net Income After Taxes | -297 | -416 | -238 | -388 | 493 |
Net Income Before Extraordinary Items | |||||
Net Income | -297 | -416 | -238 | -388 | 493 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -297 | -416 | -238 | -388 | 493 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -87.2 | -66.2 | -73.6 | -65.3 | 97.4 |
Dividends per Share |